Real-time enrollment status for this transthyretin amyloidosis cardiomyopathy (attr-cm) clinical trial
Current Status
Recruiting
Checked: August 28, 2026 at 5:58 PM UTC
| NCT Number | NCT07695701 |
| Recruiting Status | Recruiting |
| Condition | Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) |
| Phase | PHASE4 |
| Target Enrollment | 150 participants |
| Active Locations | 1 sites in the US |
| Sponsor | Eidos Therapeutics, a BridgeBio company |
| Last Updated on CT.gov | July 29, 2026 (Jul 29, 2026) |
As of August 28, 2026: Clinical trial NCT07695701 is currently recruiting participants. This phase4 study for transthyretin amyloidosis cardiomyopathy (attr-cm) is actively seeking new participants at 1 location across the United States. The study is sponsored by Eidos Therapeutics, a BridgeBio company. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07695701 is actively recruiting participants as of August 28, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 1 location in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07695701 was last updated Jul 29, 2026 (July 29, 2026). HelloStudys verifies this status automatically.